scholarly journals Altered age‐linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT‐preAD study) with high brain amyloid load

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Jean M. Delabar ◽  
Marion Ortner ◽  
Stephanie Simon ◽  
Anne Wijkhuisen ◽  
Cecile Feraudet‐Tarisse ◽  
...  
Keyword(s):  
High Brain ◽  
Amyloid Load

In vivo imaging of beta-amyloid load in transgenic rodents with [F-18]FDDNP microPET

2005 ◽  
Vol 25 (1_suppl) ◽  
pp. S588-S588
Author(s):  
Vladimir Kepe ◽  
Gregory M Cole ◽  
Jie Liu ◽  
Dorothy G Flood ◽  
Stephen P Trusko ◽  
...  
Keyword(s):  
In Vivo Imaging ◽  
Beta Amyloid ◽  
Amyloid Load

Regression of cardiac amyloid deposits with novel therapeutics: reaching new frontiers in cardiac ATTR amyloidosis

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
L Chacko ◽  
A Martinez-Naharro ◽  
T Kotecha ◽  
R Martone ◽  
D Hutt ◽  
...  
Keyword(s):  
Treatment Group ◽  
Cardiac Amyloidosis ◽  
T1 Mapping ◽  
Group Versus ◽  
Control Group ◽  
Cardiac Amyloid ◽  
Attr Amyloidosis ◽  
Amyloid Load ◽  
The Impact

Abstract Background Cardiac involvement is the main driver of outcome in ATTR amyloidosis. Advances in therapeutics hold potential in transforming the course of the disease but the impact on cardiac amyloid load is unknown. The aim of this study was to evaluate the impact of patisiran, a new double stranded RNA based gene silencing therapy and a stabilizer, diflunisal, on cardiac amyloid load as measured by CMR and T1 mapping, in patients with ATTR amyloidosis. Methods and results Thirty-two patients with hereditary cardiac amyloidosis were studied. Sixteen patients received treatment with patisiran, and sixteen control subjects did not receive any disease modifying treatment. Patients were assessed with echocardiogram, CMR, NT-proBNP and six-minute walk time measurements at baseline and at 1 year (Mean interval 11.45±3.08 months in treatment group, mean interval 12.82±5.06 months in the control group). CMR analysis comprised LV volumes, T1 mapping to measure the extracellular volume (ECV) occupied by amyloid, T2 mapping and late gadolinium enhancement imaging. At 1-year follow-up, there was a substantial reduction in cardiac amyloid burden, in keeping with cardiac amyloid regression in 45% of patients on treatment. Overall the treatment group showed a reduction in ECV at 1 year follow up compared to an increase in ECV at 1 year in the control group (−1.37%, 95% CI: −3.43 to 0.68% versus 5.02%, 95% CI: 2.86% to 7.18% respectively, p<0.001). The treatment group also showed an improvement in change in 6MWT at 1 year follow up compared to 6MWT at 1 year in the control group (−8.12 meters, 95% CI: −50.8 to 34.6 meters in the treatment group versus −132.27 meters, 95% CI: −216 to −48.6 meters in the control group, p=0.002). The treatment group showed a reduction in BNP at 1 year follow up compared to an increase in the control group (−567.87, 95% CI: −1288.90 to 153.15 in the treatment group versus 2004, 95% CI: 12.82 to 3995.45 in the control group, p<0.001). There was no significant difference from baseline and 1-year data between the control and treatment groups for the difference in echocardiographic parameters, native T1, T2. There was a significant reduction in the percentage of injected dose by 99Tc-DPD scintigraphy in treated patients at 1 year compared to baseline. Conclusions These findings provide the first compelling evidence of substantial cardiac amyloid regression in ATTR amyloidosis, as well as the potential for CMR to be used to track response in treated patients with ATTR cardiac amyloidosis. Combination therapy with transthyretin knock down and stabilizing agents may well be synergistic given enhanced stoichiometry of stabilizers in the face of much reduced plasma transthyretin concentration. Funding Acknowledgement Type of funding source: None

scholarly journals Effects of optogenetic stimulation of basal forebrain parvalbumin neurons on Alzheimer’s disease pathology

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Caroline A. Wilson ◽  
Sarah Fouda ◽  
Shuzo Sakata
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Basal Forebrain ◽  
Gamma Oscillations ◽  
Cortical Region ◽  
Sensory Stimuli ◽  
Beneficial Effects ◽  
Amyloid Load ◽  
5Xfad Mice ◽  
Frontal Cortical Region

Abstract Neuronal activity can modify Alzheimer’s disease pathology. Overexcitation of neurons can facilitate disease progression whereas the induction of cortical gamma oscillations can reduce amyloid load and improve cognitive functions in mouse models. Although previous studies have induced cortical gamma oscillations by either optogenetic activation of cortical parvalbumin-positive (PV+) neurons or sensory stimuli, it is still unclear whether other approaches to induce gamma oscillations can also be beneficial. Here we show that optogenetic activation of PV+ neurons in the basal forebrain (BF) increases amyloid burden, rather than reducing it. We applied 40 Hz optical stimulation in the BF by expressing channelrhodopsin-2 (ChR2) in PV+ neurons of 5xFAD mice. After 1-h induction of cortical gamma oscillations over three days, we observed the increase in the concentration of amyloid-β42 in the frontal cortical region, but not amyloid-β40. Amyloid plaques were accumulated more in the medial prefrontal cortex and the septal nuclei, both of which are targets of BF PV+ neurons. These results suggest that beneficial effects of cortical gamma oscillations on Alzheimer’s disease pathology can depend on the induction mechanisms of cortical gamma oscillations.

Cognitive change in frail individuals with intermediate amyloid load: Insight from the MAPT interventional study (+ Running poster)

2021 ◽  
Vol 45 (4) ◽  
pp. 217-218
Author(s):  
L. Saint-Aubert ◽  
I. Carrié ◽  
A. Hitzel ◽  
A. Salabert ◽  
B. Vellas ◽  
...  
Keyword(s):  
Cognitive Change ◽  
Interventional Study ◽  
Amyloid Load

Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains

1997 ◽  
Vol 18 (1) ◽  
pp. 121-127 ◽  
Author(s):  
T. Pirttilä ◽  
H. Soininen ◽  
P.D. Mehta ◽  
O. Heinonen ◽  
T. Lehtimäki ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Apolipoprotein E ◽  
Amyloid Load ◽  
And Control ◽  
Apolipoprotein E Genotype

Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults

Neurology ◽  
2012 ◽  
Vol 79 (16) ◽  
pp. 1645-1652 ◽  
Author(s):  
Y. Y. Lim ◽  
K. A. Ellis ◽  
R. H. Pietrzak ◽  
D. Ames ◽  
D. Darby ◽  
...  
Keyword(s):  
Older Adults ◽  
Cognitive Decline ◽  
Apoe Genotype ◽  
Healthy Older Adults ◽  
Amyloid Load

IC-P-033: CORRESPONDENCE BETWEEN [C-11]PIB PET AND POST-MORTEM MEASURES OF AMYLOID LOAD IN THE PRECUNEUS: THE ROLE OF DIFFUSE Aβ PLAQUES

2014 ◽  
Vol 10 ◽  
pp. P21-P21
Author(s):  
Julie Price ◽  
Eric E. Abrahamson ◽  
Lan Shao ◽  
Carl R. Becker ◽  
Manik L. Debnath ◽  
...  
Keyword(s):  
Post Mortem ◽  
Amyloid Load

Small Vessel Disease, but Neither Amyloid Load nor Metabolic Deficit, Is Dependent on Age at Onset in Alzheimer’s Disease

2015 ◽  
Vol 77 (8) ◽  
pp. 704-710 ◽  
Author(s):  
Marion Ortner ◽  
Alexander Kurz ◽  
Panagiotis Alexopoulos ◽  
Florian Auer ◽  
Janine Diehl-Schmid ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Small Vessel Disease ◽  
Age At Onset ◽  
Small Vessel ◽  
Vessel Disease ◽  
Amyloid Load

scholarly journals Fecal Microbiota Transplantation Decreases Amyloid Load and Improves Cognition in Alzheimer’s

2019 ◽  
Author(s):  
Shalini Elangovan ◽  
Thomas J Borody ◽  
R M Damian Holsinger
Keyword(s):  
Alzheimer’S Disease ◽  
Recognition Memory ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Therapeutic Effects ◽  
Wild Type ◽  
Neuroprotective Effects ◽  
Amyloid Pathology ◽  
Amyloid Load ◽  
Old Mice

AbstractThe efficacy of fecal microbiota transplantation (FMT) in Alzheimer’s disease has yet to be investigated. Here, we show that FMT is capable of providing neuroprotective effects in two groups of treated 5xFAD Alzheimer’s mice, old transgenic (Tg) mice fed fecal slurry from healthy, wild-type donors of similar age (Old Tg-FO) and old mice fed fecal slurry from younger healthy, wild-type donors (Old Tg-FY). Improved spatial and recognition memory in Old Tg-FY and enhanced recognition memory in Old Tg-FO were observed when compared to Old Tg-Control mice given saline. Crucially, there was significant decreases in cortical Aβ loading in all treated mice, demonstrating the therapeutic effects of FMT in improving cognition and reducing amyloid pathology in AD brains.One Sentence SummaryFecal microbial transplants reduce amyloid pathology and improve cognition in Alzheimer’s mice.

Sign in / Sign up

Export Citation Format

Share Document